» Articles » PMID: 36246517

Atherosclerosis Risk Factors in Patients with Reactive Hypoglycemia

Overview
Publisher Dove Medical Press
Specialty Endocrinology
Date 2022 Oct 17
PMID 36246517
Authors
Affiliations
Soon will be listed here.
Abstract

Purpose: Glucose metabolism disorders are an established risk factor for atherosclerosis. Although reactive hypoglycemia (RH) can be classified as one of these disorders, its role as a potential atherosclerosis risk factor remains unclear. The aim of the study was to assess whether patients with RH have a higher risk of atherosclerosis.

Patients And Methods: We recruited 178 patients (N=178) with suspected RH who were hospitalized after 2014 and underwent a prolonged 5-hour oral glucose tolerance test. The study cohort was divided into 2 groups depending on the results of the oral glucose tolerance test: Group 1 - subjects without RH (n=44), Group 2 -subjects with RH (n=134).

Results: The analyzed groups differed significantly in terms of the following risk factors for atherosclerosis: high-density lipoprotein (HDL) cholesterol levels (54.3±18.8 mg/dL vs 63±18.5 mg/dL, p=0.003) and atherogenic indices (Castelli I: 3.7±1.2 vs 3.1±1.3, p=0.004; Castelli II: 2.1±0.9 vs 1.7±0.9, p=0.007; the atherogenic index of plasma: 0.34±0.33 vs 0.18±0.3, p=0.006; and the atherogenic coefficient: 2.7±1.2 vs 2.1±1.3, p=0.004). Univariate logistic regression showed that RH should not be considered to be a predictor of an increased atherogenic index of plasma (odds ratio [OR]=0.3 [95% confidence interval [CI] [0.16-0.7], p=0.002). Multivariate logistic regression revealed triglyceride levels (OR 1.14 [1.07-1.2], p=0.001) and body weight (OR 1.07 [1.03-1.12], p=0.002) to be independent risk factors for atherosclerosis.

Conclusion: Atherosclerosis risk factors are no more prevalent in patients with RH. RH does not increase the risk of an abnormal atherogenic index of plasma.

Citing Articles

High Atherogenic Risk in Ketosis-Prone Type 2 Diabetic Individuals with Ketosis Episodes: A Cross-Sectional Study.

He X, Luo Y, Hao J, Hu R, Yang X, Ren L Diabetes Metab Syndr Obes. 2023; 16:3085-3094.

PMID: 37818406 PMC: 10561756. DOI: 10.2147/DMSO.S421203.


Key ingredients in and determination of their anti-atherosclerotic effect using a computer-aided drug design approach.

Chen Y, Gan Y, Yu J, Ye X, Yu W Front Plant Sci. 2023; 14:1154266.

PMID: 37077636 PMC: 10106644. DOI: 10.3389/fpls.2023.1154266.

References
1.
Visseren F, Mach F, Smulders Y, Carballo D, Koskinas K, Back M . 2021 ESC Guidelines on cardiovascular disease prevention in clinical practice. Eur Heart J. 2021; 42(34):3227-3337. DOI: 10.1093/eurheartj/ehab484. View

2.
Akici N, Onal Z, Gurbuz T, Sag C, Kilinc S . ATHEROGENIC INDICES IN THE ASSESSMENT OF CARDIOVASCULAR DISEASE RISK IN CHILDREN WITH OBESITY AND SUBCLINICAL HYPOTHYROIDISM. Acta Endocrinol (Buchar). 2020; 16(3):334-338. PMC: 7748231. DOI: 10.4183/aeb.2020.334. View

3.
Edwards M, Blaha M, Loprinzi P . Atherogenic Index of Plasma and Triglyceride/High-Density Lipoprotein Cholesterol Ratio Predict Mortality Risk Better Than Individual Cholesterol Risk Factors, Among an Older Adult Population. Mayo Clin Proc. 2017; 92(4):680-681. DOI: 10.1016/j.mayocp.2016.12.018. View

4.
Di Pino A, DeFronzo R . Insulin Resistance and Atherosclerosis: Implications for Insulin-Sensitizing Agents. Endocr Rev. 2019; 40(6):1447-1467. PMC: 7445419. DOI: 10.1210/er.2018-00141. View

5.
. Hypoglycaemia, cardiovascular disease, and mortality in diabetes: epidemiology, pathogenesis, and management. Lancet Diabetes Endocrinol. 2019; 7(5):385-396. DOI: 10.1016/S2213-8587(18)30315-2. View